Accueil>>Signaling Pathways>> Endocrinology and Hormones>> Androgen Receptor>>AZD3514

AZD3514

Catalog No.GC10372

AZD3514 est un inhibiteur sélectif des récepteurs aux androgènes (RA) actif par voie orale. AZD3514 inhibe le signal AR de manière dépendante et indépendante des androgènes. AZD351 régule À la baisse les niveaux d'AR nucléaire dans les cellules cancéreuses de la prostate humaines LNCaP en l'absence d'androgènes avec une valeur de pIC50 de 5,75. AZD3514 peut être utilisé pour la recherche sur le cancer de la prostate.

Products are for research use only. Not for human use. We do not sell to patients.

AZD3514 Chemical Structure

Cas No.: 1240299-33-5

Taille Prix Stock Qté
10mM (in 1mL DMSO)
77,00 $US
En stock
5mg
67,00 $US
En stock
10mg
117,00 $US
En stock
50mg
335,00 $US
En stock
100mg
544,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

AZD3514 is a potent and oral androgen receptor (AR) inhibitor with Ki value of 2.2 μM [1].
AR is a member of the steroid hormone receptor family and functions as a ligand-dependent transcription factor. AR signaling participates in the antiandrogen therapies [2].
In LNCaP and LAPC4 prostate cancer cells, AZD3514 inhibited DHT-driven proliferation of LNCaP cells in a dose-dependent way and inhibited the ligand-driven expression of AR-regulated genes PSA and TMPRSS2. Also, AZD3514 reduced AR protein expression in a dose-dependent way [2].
In male Copenhagen rats with prostate tumors, Oral treatment of AZD3514 (50 mg/kg) once daily inhibited tumor growth by 64%. Also, AZD3514 reduced nuclear AR protein expression. In the Dunning R3327H tumor model, treatment with AZD3514 significantly reduced AR staining in the nucleus of tumor cells, which were caused by reducing the rate of AR synthesis [2].
References:
[1]. Bradbury RH, Acton DG, Broadbent NL, et al. Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorg Med Chem Lett, 2013, 23(7): 1945-1948.
[2]. Loddick SA, Ross SJ, Thomason AG, et al. AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther, 2013, 12(9): 1715-1727.

Avis

Review for AZD3514

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AZD3514

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.